[
  {
    "ts": null,
    "headline": "Expansion of U.S. Manufacturing and Tezspire Approval Might Change the Case for Investing in Amgen (AMGN)",
    "summary": "Amgen recently announced a US$650 million expansion of its U.S. manufacturing network, including upgrades at its Juncos facility and nearly 750 new jobs, while its co-developed medicine Tezspire received a positive recommendation in the EU for treating chronic rhinosinusitis with nasal polyps based on successful phase 3 trial results. The manufacturing investment and regulatory progress for Tezspire point to Amgen's ongoing efforts to strengthen domestic production and expand its reach in...",
    "url": "https://finnhub.io/api/news?id=841b69d3e7989f130d5d098bca3bbf948950e9af304c6b2d56f8ac0d519f21b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758980518,
      "headline": "Expansion of U.S. Manufacturing and Tezspire Approval Might Change the Case for Investing in Amgen (AMGN)",
      "id": 136904125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen recently announced a US$650 million expansion of its U.S. manufacturing network, including upgrades at its Juncos facility and nearly 750 new jobs, while its co-developed medicine Tezspire received a positive recommendation in the EU for treating chronic rhinosinusitis with nasal polyps based on successful phase 3 trial results. The manufacturing investment and regulatory progress for Tezspire point to Amgen's ongoing efforts to strengthen domestic production and expand its reach in...",
      "url": "https://finnhub.io/api/news?id=841b69d3e7989f130d5d098bca3bbf948950e9af304c6b2d56f8ac0d519f21b2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Strong R&D Pipeline Drives Growth Outlook",
    "summary": "Regeneron remains a 'Strong Buy' amid investor concerns and strong drug performances. Read here for more financial analysis of REGN stock.",
    "url": "https://finnhub.io/api/news?id=3d4ba0704f1a3d97b6cda52ebfecc661b38899c3e02c095bd67bce24888f884c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758963632,
      "headline": "Regeneron: Strong R&D Pipeline Drives Growth Outlook",
      "id": 136900904,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/904246150/image_904246150.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron remains a 'Strong Buy' amid investor concerns and strong drug performances. Read here for more financial analysis of REGN stock.",
      "url": "https://finnhub.io/api/news?id=3d4ba0704f1a3d97b6cda52ebfecc661b38899c3e02c095bd67bce24888f884c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie For Healthy Dividend Growth",
    "summary": "AbbVie combines strong earnings, rising dividends, and growth from Skyrizi and Rinvoq, making it a top dividend pick. Read why ABBV stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=7c660737d9e119b19951c43ee9d6fe728274ef93d8d4956dfdd339ce01f2c0b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758956453,
      "headline": "AbbVie For Healthy Dividend Growth",
      "id": 136900538,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "AbbVie combines strong earnings, rising dividends, and growth from Skyrizi and Rinvoq, making it a top dividend pick. Read why ABBV stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=7c660737d9e119b19951c43ee9d6fe728274ef93d8d4956dfdd339ce01f2c0b5"
    }
  }
]